| abstract |
Described are compounds that inhibit mitogen active protein kinase-active protein kinase-2 (MK-2). A method for preparing the compound, and a method of using the same for inhibiting MK-2, and a method for using the same in the prevention or treatment of a disease or disorder mediated by TNFα are described. Administering an MK-2 inhibitory compound. Pharmaceutical compositions and kits containing such MK-2 inhibitory compounds are also described. |